Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. [electronic resource]
Producer: 20090105Description: 7272-83 p. digitalISSN:- 1078-0432
- Angiogenesis Inhibitors -- pharmacology
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Axitinib
- Blotting, Western
- Cell Line, Tumor
- Drug Synergism
- Female
- Humans
- Imidazoles -- pharmacology
- Immunohistochemistry
- Immunoprecipitation
- Indazoles -- pharmacology
- Mice
- Mice, Nude
- Neoplasms, Experimental -- drug therapy
- Neovascularization, Pathologic -- drug therapy
- Protein Kinase Inhibitors -- pharmacology
- Receptors, Vascular Endothelial Growth Factor -- antagonists & inhibitors
- Signal Transduction -- drug effects
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.